|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM326795898 |
| 003 |
DE-627 |
| 005 |
20250301221313.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1111/vcp.12953
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1089.xml
|
| 035 |
|
|
|a (DE-627)NLM326795898
|
| 035 |
|
|
|a (NLM)34131937
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Buriko, Yekaterina
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Utility of the Sonoclot analyzer to assess hyperfibrinolysis in dogs
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.08.2021
|
| 500 |
|
|
|a Date Revised 30.08.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 American Society for Veterinary Clinical Pathology.
|
| 520 |
|
|
|a BACKGROUND: Coagulation abnormalities, including hyperfibrinolysis, have been documented in sick veterinary patients. Viscoelastic tests, including the Sonoclot Coagulation and Platelet Function Analyzer, are useful in detecting hyperfibrinolysis. Tissue plasminogen activator (tPA) assays have been used to quantify fibrinolysis using thromboelastography
|
| 520 |
|
|
|a OBJECTIVES: We aimed to document and evaluate changes in the whole blood of healthy dogs exposed to in vitro tPA at varying concentrations using the Sonoclot analyzer
|
| 520 |
|
|
|a METHODS: Ten milliliters of blood was collected from healthy adult dogs. Sonoclot tests were run in duplicate and included a control sample and five tPA concentrations: 50, 75, 100, 150, and 200 IU/mL of blood
|
| 520 |
|
|
|a RESULTS: Eleven dogs were enrolled in the study. Based on standard Sonoclot Signature changes, a numeric value fibrinolysis time (FTi) was derived to aid in the quantification of hyperfibrinolysis. Activated clotting time and clot rate Sonoclot values were not significantly affected by any tPA concentration. There was a significant decrease in platelet function (PF) at tPA concentrations equal to and above 75 IU/mL on channel 1 and tPA concentrations of 150 IU/mL and higher on channel 2. There was a progressive decrease in FTi at increasing tPA concentrations
|
| 520 |
|
|
|a CONCLUSIONS: The Sonoclot analyzer can be used to evaluate hyperfibrinolysis. Predictable changes were seen in the Sonoclot Signature and a decrease in PF and FTi was found with increasing tPA concentrations. The Sonoclot assay with a tPA concentration of 100 IU/mL is suggested a baseline measure of hyperfibrinolysis and has a resultant median FTi of 42 minutes, which is a practical time for clinical applications
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a analyzer
|
| 650 |
|
4 |
|a coagulation
|
| 650 |
|
4 |
|a fibrinolysis
|
| 650 |
|
4 |
|a hemostasis
|
| 650 |
|
4 |
|a viscoelastic
|
| 650 |
|
7 |
|a Tissue Plasminogen Activator
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.68
|2 NLM
|
| 700 |
1 |
|
|a Hess, Rebecka S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pfeifer, Julie M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Silverstein, Deborah C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Veterinary clinical pathology
|d 1975
|g 50(2021), 2 vom: 16. Juni, Seite 178-183
|w (DE-627)NLM098159984
|x 1939-165X
|7 nnas
|
| 773 |
1 |
8 |
|g volume:50
|g year:2021
|g number:2
|g day:16
|g month:06
|g pages:178-183
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1111/vcp.12953
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 50
|j 2021
|e 2
|b 16
|c 06
|h 178-183
|